Global pharmaceutical firm Eli Lilly and Co. will invest $3.5 billion to build a manufacturing plant in Upper Macungie Township that is expected to create 850 jobs. “This is the largest single project ...
Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. Eli Lilly's ...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making ...
Eli Lilly LLY3.66%increase; green up pointing triangle is in advanced talks to acquire Ventyx Biosciences VTYX 0.14%increase; green up pointing triangle for around $1 billion, according to people ...
Jan 6 (Reuters) - Eli Lilly (LLY.N), opens new tab is in advanced talks to buy Ventyx Biosciences (VTYX.O), opens new tab for more than $1 billion, the Wall Street Journal reported on Tuesday, citing ...
This is read by an automated voice. Please report any issues or inconsistencies here. Evangeline Lilly says much of her brain is “functioning at a decreased capacity” after her traumatic brain injury ...
Evangeline Lilly revealed on social media that she has brain damage after suffering a concussion last year when she fell into a boulder. The “Lost” and “Ant-Man” star said that “almost every area in ...
Evangeline Lilly says she has brain damage, months after fainting and hitting her head on a rock while at the beach. “It’s late on January 1st. The first day of 2026. And I’m entering into this new ...
Evangeline Lilly is sharing an update on her health following an unfortunate accident in May 2025. In an Instagram video posted on Friday, Jan. 2, the 46-year-old "Lost" star shared that she has ...
Evangeline Lilly revealed that medical tests showed she suffered brain damage following a nasty fall onto a boulder that the Lost actress endured last year. In May, Lilly wrote that she “fainted at ...
Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results